DBV DBV Technologies SA

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024

                                                               

Information relative au nombre total des droits de vote et

d’actions composant le capital social au 30 novembre 2024

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)

Place de cotation : NYSE Euronext Paris

Code ISIN : FR 0010417345



 



Date





  		Nombre total



d’actions



composant le capital social 		Nombre total



de droits de vote
30/11/2024





  		102.847.501





 

 



Total brut des droits de vote :



102.847.501





 


 



Total net* des droits de vote : 102.582.335





 

*Total net = nombre total de droits de vote attachés au nombre total d’actions – actions privées de droits de vote 

Pièce jointe



EN
02/12/2024

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO ...

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF AMF Regulated InformationChâtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2024: 266,868 DBV Technologies shares,€...

January 13, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BH...

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF Informations RéglementéesChâtillon, France, le 13 janvier 2025 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT), laboratoire biopharmaceutique français, publie aujourd’hui le bilan semestriel de son contrat de liquidité avec ODDO BHF. Au titre du contrat de liquidité confié à ODDO BHF, portant sur les actions de la société DBV TECHNOLOGIES, à la date du 31 décembre 2024, les moyens suivants figuraient au compte de liquidité...

January 13, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase ...

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergen...

January 8, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway f...

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025Viaskin Peanut patch BLA submission for the Toddlers indication anticipated ...

December 11, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information regarding the total number of voting rights and  total nu...

Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024 Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2024102,847,501Total gross of voting rights: 102,847,501Total net* of voting rights: 102,582,335 * Net total = total number of voting rights attached...

December 2, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch